Management of type 2 diabetes: More evidence is required to address the clinical and contextual facets

Current Diabetes Reviews

Volumn 7, Issue 2, 2011, Pages 99-105

  Hernandez Jimenez, Sergio ^a   Aguilar Salinas, Carlos A ^a   Mehta, Roopa ^a   Rull, Juan A ^a   Gómez Pérez, Francisco J ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Algorithms; Developing countries; Early onset type 2 diabetes; Elders; Evidence based guidelines; Intensive glucose lowering; Multidisciplinary teams

Indexed keywords

HEMOGLOBIN A1C; INSULIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

AGE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; COMORBIDITY; CONSERVATIVE TREATMENT; DIABETIC PATIENT; DISEASE DURATION; EDUCATIONAL STATUS; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; ALGORITHM; ANALYSIS; CHEMICALLY INDUCED; CHILD; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; INFANT; MIDDLE AGED; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME; WEIGHT GAIN;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALGORITHMS; BLOOD GLUCOSE; BODY WEIGHT; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFANT; MIDDLE AGED; OBESITY; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; WEIGHT GAIN;

EID: 79952996487     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339911794940710     Document Type: Review

References (36)

1. Hughes J. An algorithm for choosing among smoking cessation treatments. J Subst Abuse Treat 2008; 34: 426-32.
2. ACCORD Trial. Rationale for Study Design. Available at: www.accordtrial.org (Accessed on September 1, 2010)
3. Home PD. Impact of the UKPDS--an overview. Diabet Med 2008; 25(Suppl. 2): 2-8.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.
7. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes 2008; 57: 995-1001.
8. United Kingdom prospective diabetes study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-8.
9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1-13.
10. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33(Suppl 1): S11-61.
11. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
12. Duckworth WC, McCarren M, Abraira C. Glucose control and cardiovascular complications: The VA Diabetes Trial. Diabetes Care 2001; 24: 942-5.
13. Duckworth W, Abraira C, Moritz T, et al: VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39.
14. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
15. Hirsch IB. Piecing The Puzzle Together: According to Whom? J Clin Endocrinol Engl Metab 2008; 93: 1161-3.
16. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008; 358: 2530-3.
17. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
18. Pogach L, Aron D. Balancing hypoglycemia and glycemic control: A public health approach for insulin safety. JAMA 2010; 303: 2076-7.
19. Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin cncentration on therisk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010; 340: b5444.
20. Mitka M. Aggressive lipid, hypertension targeting yields no benefit for some with diabetes. JAMA 2010; 303: 1681-3.
21. Calles-Escandón J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33: 721-7.
22. Villalpando S, de la Cruz V, Rojas R, Shamah-Levy T, Ávila MA, Gaona B. Prevalence and distribution of type 2 diabetes mellitus in mexican adult population: a probabilistic survey. Salud Publica Mex 2010; 52(supp 1): S19-26.
23. Prato SD, LaSalle J, Matthaei S, Bailey CJ; Global Partnership for Effective Diabetes Management. Tailoring treatment to the individual in type 2 diabetes practical guidance from the global partnership for effective diabetes management. Int J Clin Pract 2010; 64: 295-304.
24. López-Maldonado FJ, Reza-Albarrán A, Suárez OJ, et al. Grado de control de factores de riesgo cardiovascular en una población de pacientes con diabetes mellitus tipo 1 y 2 de difícil manejo. Gac Med Mex 2009; 145: 1-6.
25. Changes to the Diabetes Recognition Program. Available at: (Accessed on September 1, 2010)http://www.ncqa.org/tabid/1023/Default.aspx (Accessed on September 1, 2010)
26. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-72.
27. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
28. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-72.
29. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53: 1270-87.
30. Sinha A, Rajan M, Hoerger T, Pogach L. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes Care 2010; 33: 695-700.
31. Lerario AC, Chacra AR, Pimazoni-Netto A, et al. Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society. Diabetol Metab Syndr 2010; 2: 35-42.
32. Deyo JP, Ramsey RA. Evidence-Based Clinical Practice: Concepts and Approaches. Butterworth-Heinemann. Boston, USA 2000.
33. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312: 71-2.
34. Gandhi GY, Murad MH, Fujiyoshi A, et al. Patient-important outcomes in registered diabetes trials. JAMA 2008; 299: 2543-9.
35. Hirsch IB, Brownlee M. Beyond Hemoglobin A1c: Need for additional markers of risk for diabetic microvascular complications. JAMA 2010; 303: 2291-2.
36. Eldor R, Raz I. The Individualized Target HbA1c: A new method for improving macrovascular risk and glycemia without hypoglycemia and weight gain. Rev Diabet Stud 2009; 6: 6-12.